Industry News
Research, Science & Manufacturer Updates
Empliciti (elotuzumab) in combination with Revlimid (lenalidomide) and dexamethasone (a type of corticosteroid) has been approved by the U.S. Food and Drug Administration to treat individuals with multiple myeloma who have received one to three prior medications.
The Centers for Medicare and Medicaid Services will implement a new primary care payment model affecting up to 5,000 practices and more than than 20,000 clinicians.
The Centers for Medicare and Medicaid Services issued a final rule mandating prior authorization for durable medical equipment.
A new study found that seasonal flu vaccines work better if they stimulate an immune response to the flu surface protein neuraminidase.
Two young adult male dogs with severe hemophilia A treated with liver-targeted gene therapy experienced significant improvement in disease phenotype over follow-up periods of 31 months and 24 months, according to investigators at The Children’s Hospital of Philadelphia and the University of Pennsylvania.
The Medicare Rights Center has launched Medicare Interactive (MI), a free online resource with hundreds of answers to Medicare questions.
The Centers for Medicare and Medicaid Services published its annual Notice of Benefit and Payment Parameters, which governs participation in the Affordable Care Act health insurance marketplaces for 2017.
The Centers for Disease Control and Prevention (CDC) has released the CDC Guideline for Prescribing Opioids for Chronic Pain.
Researchers found that flu vaccines are more effective when given in the morning because patients’ immune systems are capable of producing more antibodies in response to the vaccine in the first part of the day.
Using technology that allows scientists to read the script of a person’s DNA, scientists have found a new autoimmune disease syndrome that combines severe lung disease and arthritis.
Baxalta has begun a Phase I, first-inhuman clinical trial of BAX 826, a recombinant factor VIII (rFVIII) treatment for hemophilia A that uses proprietary polysialic acid (PSA) technology to extend its circulating half-life.